ArticleThe Journal of biological chemistry2013
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.
Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases.Science advances · 2025Article
- Development of multi-epitope Cathepsin L driven short peptide vaccine againstFrontiers in veterinary science · 2025Article
- Feature Selection Enhances Peptide Binding Predictions for TCR-Specific Interactions.bioRxiv : the preprint server for biology · 2024Article
- Feature selection enhances peptide binding predictions for TCR-specific interactions.Frontiers in immunology · 2024Article
- Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes.Cancer immunology research · 2023Article
- Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma.Frontiers in immunology · 2022Article
- Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.Frontiers in immunology · 2022Article
- Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.Journal for immunotherapy of cancer · 2021Article
- T-cell receptor affinity in the age of cancer immunotherapy.Molecular carcinogenesis · 2020Review
- Peptide mimotopes alter T cell function in cancer and autoimmunity.Seminars in immunology · 2020Review
- Microglial Cells: The Main HIV-1 Reservoir in the Brain.Frontiers in cellular and infection microbiology · 2019Review
- Unimicellar hyperstars as multi-antigen cancer nanovaccines displaying clustered epitopes of immunostimulating peptides.Biomaterials science · 2018Article
- Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Human vaccines & immunotherapeutics · 2016Review
- Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.European journal of immunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Vaccines that incorporate peptide mimics of tumor antigens, or mimotope vaccines, are commonly used in cancer immunotherapy and function by eliciting increased numbers of T cells that cross-react with the native tumor antigen. Unfortunately, they often elicit T cells that do not cross-react with or that have low affinity for the tumor antigen. Using a high affinity tumor-specific T cell clone, we identified a panel of mimotope vaccines for the dominant peptide antigen from a mouse colon tumor that elicits a range of tumor protection following vaccination. The TCR from this high affinity T cell clone was rarely identified in ex vivo evaluation of tumor-specific T cells elicited by mimotope vaccination. Conversely, a low affinity clone found in the tumor and following immunization was frequently identified. Using peptide libraries, we determined if this frequently identified TCR improved the discovery of efficacious mimotopes. We demonstrated that the representative TCR identified more protective mimotopes than the high affinity TCR. These results suggest that targeting a dominant fraction of tumor-specific T cells generates potent immunity and that consideration of the available T cell repertoire is necessary for targeted T cell therapy. These results have important implications when optimizing mimotope vaccines for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.